Do analysts recommend SBFM or ALBT?

Sunshine Biopharma presently has a consensus target price of $70.00, suggesting a potential upside of 3,186.38%. Given Sunshine Biopharma's stronger consensus rating and higher probable upside, research analysts clearly believe Sunshine Biopharma is more favorable than Avalon GloboCare. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sunshine Biopharma 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Avalon GloboCare 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend RDHL or SBFM?

Sunshine Biopharma has a consensus price target of $70.00, suggesting a potential upside of 3,186.38%. Given Sunshine Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Sunshine Biopharma is more favorable than Redhill Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Sunshine Biopharma 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts rate ENSC or SBFM?

Sunshine Biopharma has a consensus price target of $70.00, indicating a potential upside of 3,186.38%. Given Sunshine Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Sunshine Biopharma is more favorable than Ensysce Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ensysce Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Sunshine Biopharma 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts prefer SBFM or PPCB?

Sunshine Biopharma presently has a consensus target price of $70.00, indicating a potential upside of 3,186.38%. Given Sunshine Biopharma's stronger consensus rating and higher probable upside, research analysts plainly believe Sunshine Biopharma is more favorable than Propanc Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sunshine Biopharma 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Sunshine Biopharma (SBFM) Competitors

$2.13 0.00 (0.00%)

Closing price 06/18/2026 04:00 PM Eastern

Extended Trading

$2.10 -0.02 (-1.17%)

As of 06/18/2026 07:51 PM Eastern

Compare

SBFM vs. ALBT, RDHL, ENSC, PPCB, and GOVX

Should you buy Sunshine Biopharma stock or one of its competitors? MarketBeat compares Sunshine Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sunshine Biopharma include Avalon GloboCare (ALBT), Redhill Biopharma (RDHL), Ensysce Biosciences (ENSC), Propanc Biopharma (PPCB), and GeoVax Labs (GOVX). These companies are all part of the "pharmaceutical products" industry.

How does Sunshine Biopharma compare to Avalon GloboCare?

Sunshine Biopharma (NASDAQ:SBFM) and Avalon GloboCare (NASDAQ:ALBT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk.

Sunshine Biopharma has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market. Comparatively, Avalon GloboCare has a beta of -0.06, indicating that its share price is 106% less volatile than the broader market.

Avalon GloboCare has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -18.45%. Avalon GloboCare's return on equity of 0.00% beat Sunshine Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sunshine Biopharma	-18.45%	-27.75%	-21.57%
Avalon GloboCare	N/A	N/A	-74.36%

Sunshine Biopharma has higher revenue and earnings than Avalon GloboCare. Sunshine Biopharma is trading at a lower price-to-earnings ratio than Avalon GloboCare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sunshine Biopharma	$36.31M	0.03	-$5.97M	-$12.90	N/A
Avalon GloboCare	$1.26M	3.25	-$18.26M	-$3.51	N/A

42.0% of Sunshine Biopharma shares are held by institutional investors. Comparatively, 1.4% of Avalon GloboCare shares are held by institutional investors. 0.5% of Sunshine Biopharma shares are held by insiders. Comparatively, 24.2% of Avalon GloboCare shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Avalon GloboCare had 1 more articles in the media than Sunshine Biopharma. MarketBeat recorded 1 mentions for Avalon GloboCare and 0 mentions for Sunshine Biopharma. Sunshine Biopharma's average media sentiment score of 0.00 equaled Avalon GloboCare'saverage media sentiment score.

Company	Overall Sentiment
Sunshine Biopharma	Neutral
Avalon GloboCare	Neutral

Sunshine Biopharma presently has a consensus target price of $70.00, suggesting a potential upside of 3,186.38%. Given Sunshine Biopharma's stronger consensus rating and higher probable upside, research analysts clearly believe Sunshine Biopharma is more favorable than Avalon GloboCare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sunshine Biopharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Avalon GloboCare	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Sunshine Biopharma beats Avalon GloboCare on 8 of the 15 factors compared between the two stocks.

How does Sunshine Biopharma compare to Redhill Biopharma?

Redhill Biopharma (NASDAQ:RDHL) and Sunshine Biopharma (NASDAQ:SBFM) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and media sentiment.

Redhill Biopharma has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -18.45%. Redhill Biopharma's return on equity of 0.00% beat Sunshine Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Redhill Biopharma	N/A	N/A	N/A
Sunshine Biopharma	-18.45%	-27.75%	-21.57%

7.2% of Redhill Biopharma shares are held by institutional investors. Comparatively, 42.0% of Sunshine Biopharma shares are held by institutional investors. 6.8% of Redhill Biopharma shares are held by insiders. Comparatively, 0.5% of Sunshine Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Redhill Biopharma has higher earnings, but lower revenue than Sunshine Biopharma. Sunshine Biopharma is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Redhill Biopharma	$290K	14.56	-$430K	$1.05 thousand	0.00
Sunshine Biopharma	$36.31M	0.03	-$5.97M	-$12.90	N/A

In the previous week, Redhill Biopharma had 2 more articles in the media than Sunshine Biopharma. MarketBeat recorded 2 mentions for Redhill Biopharma and 0 mentions for Sunshine Biopharma. Redhill Biopharma's average media sentiment score of 0.00 equaled Sunshine Biopharma'saverage media sentiment score.

Company	Overall Sentiment
Redhill Biopharma	Neutral
Sunshine Biopharma	Neutral

Sunshine Biopharma has a consensus price target of $70.00, suggesting a potential upside of 3,186.38%. Given Sunshine Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Sunshine Biopharma is more favorable than Redhill Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sunshine Biopharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Redhill Biopharma has a beta of 4.98, indicating that its stock price is 398% more volatile than the broader market. Comparatively, Sunshine Biopharma has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market.

Summary

Redhill Biopharma beats Sunshine Biopharma on 10 of the 15 factors compared between the two stocks.

How does Sunshine Biopharma compare to Ensysce Biosciences?

Ensysce Biosciences (NASDAQ:ENSC) and Sunshine Biopharma (NASDAQ:SBFM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

Ensysce Biosciences has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market. Comparatively, Sunshine Biopharma has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market.

Sunshine Biopharma has a net margin of -18.45% compared to Ensysce Biosciences' net margin of -250.39%. Sunshine Biopharma's return on equity of -27.75% beat Ensysce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ensysce Biosciences	-250.39%	-766.45%	-256.59%
Sunshine Biopharma	-18.45%	-27.75%	-21.57%

In the previous week, Ensysce Biosciences' average media sentiment score of 0.00 equaled Sunshine Biopharma'saverage media sentiment score.

Company	Overall Sentiment
Ensysce Biosciences	Neutral
Sunshine Biopharma	Neutral

5.6% of Ensysce Biosciences shares are held by institutional investors. Comparatively, 42.0% of Sunshine Biopharma shares are held by institutional investors. 2.8% of Ensysce Biosciences shares are held by insiders. Comparatively, 0.5% of Sunshine Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Sunshine Biopharma has a consensus price target of $70.00, indicating a potential upside of 3,186.38%. Given Sunshine Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Sunshine Biopharma is more favorable than Ensysce Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ensysce Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sunshine Biopharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Sunshine Biopharma has higher revenue and earnings than Ensysce Biosciences. Sunshine Biopharma is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ensysce Biosciences	$5.07M	0.84	-$10.18M	-$3.35	N/A
Sunshine Biopharma	$36.31M	0.03	-$5.97M	-$12.90	N/A

Summary

Sunshine Biopharma beats Ensysce Biosciences on 10 of the 14 factors compared between the two stocks.

How does Sunshine Biopharma compare to Propanc Biopharma?

Sunshine Biopharma (NASDAQ:SBFM) and Propanc Biopharma (NASDAQ:PPCB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.

Sunshine Biopharma presently has a consensus target price of $70.00, indicating a potential upside of 3,186.38%. Given Sunshine Biopharma's stronger consensus rating and higher probable upside, research analysts plainly believe Sunshine Biopharma is more favorable than Propanc Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sunshine Biopharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Sunshine Biopharma has higher revenue and earnings than Propanc Biopharma. Sunshine Biopharma is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sunshine Biopharma	$36.31M	0.03	-$5.97M	-$12.90	N/A
Propanc Biopharma	N/A	N/A	-$58.92M	-$24.25	N/A

42.0% of Sunshine Biopharma shares are owned by institutional investors. 0.5% of Sunshine Biopharma shares are owned by company insiders. Comparatively, 28.5% of Propanc Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Propanc Biopharma has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -18.45%. Sunshine Biopharma's return on equity of -27.75% beat Propanc Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sunshine Biopharma	-18.45%	-27.75%	-21.57%
Propanc Biopharma	N/A	-151.28%	-109.53%

Sunshine Biopharma has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market. Comparatively, Propanc Biopharma has a beta of 3.48, meaning that its stock price is 248% more volatile than the broader market.

In the previous week, Propanc Biopharma had 2 more articles in the media than Sunshine Biopharma. MarketBeat recorded 2 mentions for Propanc Biopharma and 0 mentions for Sunshine Biopharma. Sunshine Biopharma's average media sentiment score of 0.00 equaled Propanc Biopharma'saverage media sentiment score.

Company	Overall Sentiment
Sunshine Biopharma	Neutral
Propanc Biopharma	Neutral

Summary

Sunshine Biopharma beats Propanc Biopharma on 9 of the 14 factors compared between the two stocks.

How does Sunshine Biopharma compare to GeoVax Labs?

GeoVax Labs (NASDAQ:GOVX) and Sunshine Biopharma (NASDAQ:SBFM) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.

Sunshine Biopharma has higher revenue and earnings than GeoVax Labs. Sunshine Biopharma is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeoVax Labs	$2.49M	1.87	-$21.47M	-$19.12	N/A
Sunshine Biopharma	$36.31M	0.03	-$5.97M	-$12.90	N/A

GeoVax Labs has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -18.45%. Sunshine Biopharma's return on equity of -27.75% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	N/A	-709.52%	-399.33%
Sunshine Biopharma	-18.45%	-27.75%	-21.57%

GeoVax Labs has a beta of 3.62, suggesting that its stock price is 262% more volatile than the broader market. Comparatively, Sunshine Biopharma has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market.

GeoVax Labs currently has a consensus price target of $150.00, indicating a potential upside of 11,094.03%. Sunshine Biopharma has a consensus price target of $70.00, indicating a potential upside of 3,186.38%. Given GeoVax Labs' higher probable upside, equities analysts clearly believe GeoVax Labs is more favorable than Sunshine Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Sunshine Biopharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

6.1% of GeoVax Labs shares are owned by institutional investors. Comparatively, 42.0% of Sunshine Biopharma shares are owned by institutional investors. 0.7% of GeoVax Labs shares are owned by insiders. Comparatively, 0.5% of Sunshine Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, GeoVax Labs had 2 more articles in the media than Sunshine Biopharma. MarketBeat recorded 2 mentions for GeoVax Labs and 0 mentions for Sunshine Biopharma. GeoVax Labs' average media sentiment score of 0.00 equaled Sunshine Biopharma'saverage media sentiment score.

Company	Overall Sentiment
GeoVax Labs	Neutral
Sunshine Biopharma	Neutral

Summary

Sunshine Biopharma beats GeoVax Labs on 8 of the 15 factors compared between the two stocks.

Get Sunshine Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SBFM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SBFM vs. The Competition

Export

Metric	Sunshine Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.07M	$3.40B	$6.41B	$12.59B
Dividend Yield	N/A	2.32%	2.68%	5.81%
P/E Ratio	-0.17	19.90	24.56	24.44
Price / Sales	0.03	320.32	529.30	111.09
Price / Cash	N/A	56.54	27.92	37.84
Price / Book	0.05	8.15	10.81	6.60
Net Income	-$5.97M	$23.91M	$3.57B	$337.10M
7 Day Performance	-6.58%	2.18%	0.43%	-0.13%
1 Month Performance	-55.74%	0.19%	0.01%	1.75%
1 Year Performance	-85.21%	55.09%	29.35%	36.12%

Sunshine Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SBFM Sunshine Biopharma	1.7509 of 5 stars	$2.13 flat	$70.00 +3,186.4%	-85.2%	$1.07M	$36.31M	N/A	3	Gap Down
ALBT Avalon GloboCare	0.5299 of 5 stars	$0.33 +4.5%	N/A	-87.2%	$4.22M	$1.26M	N/A	5	Gap Down
RDHL Redhill Biopharma	0.6614 of 5 stars	$0.81 +2.7%	N/A	-57.2%	$4.21M	$290K	0.00	210
ENSC Ensysce Biosciences	0.7801 of 5 stars	$0.27 -2.9%	N/A	-86.2%	$4.15M	$5.07M	N/A	10	Positive News
PPCB Propanc Biopharma	0.752 of 5 stars	$1.80 -7.0%	N/A	-98.5%	$4.14M	N/A	N/A	1	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SBFM) was last updated on 6/22/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sunshine Biopharma (SBFM) Competitors

SBFM vs. ALBT, RDHL, ENSC, PPCB, and GOVX

How does Sunshine Biopharma compare to Avalon GloboCare?

Summary

How does Sunshine Biopharma compare to Redhill Biopharma?

Summary

How does Sunshine Biopharma compare to Ensysce Biosciences?

Summary

How does Sunshine Biopharma compare to Propanc Biopharma?

Summary

How does Sunshine Biopharma compare to GeoVax Labs?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SBFM vs. The Competition

Sunshine Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sunshine Biopharma (SBFM) Competitors

SBFM vs. ALBT, RDHL, ENSC, PPCB, and GOVX

How does Sunshine Biopharma compare to Avalon GloboCare?

Which has more risk & volatility, SBFM or ALBT?

Is SBFM or ALBT more profitable?

Which has higher valuation and earnings, SBFM or ALBT?

Do insiders and institutionals hold more shares of SBFM or ALBT?

Does the media refer more to SBFM or ALBT?

Do analysts recommend SBFM or ALBT?

Summary

How does Sunshine Biopharma compare to Redhill Biopharma?

Is RDHL or SBFM more profitable?

Do institutionals & insiders hold more shares of RDHL or SBFM?

Which has preferable earnings & valuation, RDHL or SBFM?

Does the media refer more to RDHL or SBFM?

Do analysts recommend RDHL or SBFM?

Which has more volatility & risk, RDHL or SBFM?

Summary

How does Sunshine Biopharma compare to Ensysce Biosciences?

Which has more volatility & risk, ENSC or SBFM?

Is ENSC or SBFM more profitable?

Does the media prefer ENSC or SBFM?

Do insiders and institutionals have more ownership in ENSC or SBFM?

Do analysts rate ENSC or SBFM?

Which has higher earnings and valuation, ENSC or SBFM?

Summary

How does Sunshine Biopharma compare to Propanc Biopharma?

Do analysts prefer SBFM or PPCB?

Which has stronger earnings and valuation, SBFM or PPCB?

Do institutionals & insiders have more ownership in SBFM or PPCB?

Is SBFM or PPCB more profitable?

Which has more risk & volatility, SBFM or PPCB?

Does the media favor SBFM or PPCB?

Summary

How does Sunshine Biopharma compare to GeoVax Labs?

Which has preferable earnings & valuation, GOVX or SBFM?

Is GOVX or SBFM more profitable?

Which has more risk & volatility, GOVX or SBFM?

Do analysts recommend GOVX or SBFM?

Do institutionals and insiders believe in GOVX or SBFM?

Does the media refer more to GOVX or SBFM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SBFM vs. The Competition

Sunshine Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools